Bayer Ag · XETR:BAYN
Bayer — Q1 2020 Earnings Presentation
18 slides from Bayer's earnings presentation, May 2020
Slide 1: Post Q1 Virtual Roadshow
Pictures to be updated Post Q1 Virtual Roadshow /////////// May, 2020
Slide 2: Cautionary Statements Regarding Forward-Looking Information
Cautionary Statements Regarding Forward-Looking Information This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the ac
Slide 3: Q1 2020 Results: Business Update
Q1 2020 Results Business Update /////////// Werner Baumann, CEO
Slide 4: COVID-19 affects activities
COVID-19 affects activities Status Quo 1 Employee Health 1 Securing health and safety of employees 2 Business Continuity 2 Safeguarding supply, production, logistics and business operations 3 Humanitarian Efforts 3 Health for all, hunger for none – using our expertise in health and nutrition i
Slide 5: Focused on business continuity
Focused on business continuity Q1 2020 Financial Performance € 12,845m +6% € 4,391m +10% yoy Sales yoy* EBITDA Before special items € 2.67 +10% € -793m yoy Core EPS Free Cash Flow * ∆% yoy, Fx & portfolio adj Note: All 2019 figures were re-based to reflect the change in cost allocations from enablin
Slide 6: Crop Science off to a good start
Crop Science off to a good start Sales Volume Currency In million €, ∆% yoy, Fx & portfolio adj. + 6% + 0% +6 % 6,444 6,834 Price Portfolio 0% 6% cpa sales growth, with contributions from all 0 + % regions Good growth across insecticides, fungicides, corn seed & traits and herbicides Q1'19 Q1'20
Slide 7: Pharmaceuticals performance driven by Xarelto
Pharmaceuticals performance driven by Xarelto Sales Volume Currency In million €, ∆% yoy, Fx & portfolio adj. + 7% + 1% +4 % 4,546 4,354 Price Portfolio - 3% 0% Xarelto (+19%) as main growth contributor Eylea (+1%) impacted by phasing China with softer growth partly due to phasing in Q1'19 Q1'
Slide 8: Strong demand for Consumer Health products in all regions
Strong demand for Consumer Health products in all regions Sales Volume Currency In million €, ∆% yoy, Fx & portfolio adj. + 11% + 0% 1,395 +14 % 1,398 Price Portfolio + 2% 13% - All regions with elevated demand primarily related to the COVID-19 epidemic Strong growth across categories, especiall
Slide 9: Q1 2020 Results: Financials & Outlook
Q1 2020 Results Financials & Outlook /////////// Wolfgang Nickl, CFO
Slide 10: Q1 2020 Result
Q1 2020 Result Sales EBITDA * Core EPS Free Cash Flow In million €, ∆% yoy, Fx & portfolio adj. In million €, before special items In €, Cont. Operations In € million Positive FX effect of €44 million Positive FX effect of €41 million Core financial result went from -€352 million Within expectations
Slide 11: Bridge: Core EPS to EPS (Q1 2020)
Bridge: Core EPS to EPS (Q1 2020) in € 2.6 2.4 2.2 -0.86 2 1.8 1.6 -0.63 0.13 1.4 2.67 1.2 0.37 -0.16 1 0.8 1.39 1.52 0.6 1.27 0.4 0.2 0 Core EPS Armortization / Special items Special items Tax effect EPS (Continuing Discontinuing EPS (total) EPS (total) Q1'2020 Write-down of (EBITDA relevant) finan
Slide 12: Net financial debt largely unchanged
Net financial debt largely unchanged in € million 581 243 40,000 -201 -4,242 35,000 39,641 39,018 30,000 35,399 34,068 5,000 0 Gross Financial Bonds / FX Bank Liabilities Other Financial Gross Financial Cash / Net Financial Debt Net Financial Debt Debt 31.12.2019 Liabilities Debt 31.03.2020 Other Fi
Slide 13: Outlook: Impact variables of COVID-19 situation
Outlook: Impact variables of COVID-19 situation Production and Supply Demand Dynamics CS: Demand Stability for bio-fuel of entire supply and access to chain Demand patterns, CS: Demand e.g. stockpiling for bio-fuel and access to seasonals workers seasonals workers Inventory / Safety stock Impact on
Slide 14: Focus areas 2020
Focus areas 2020 1 2 Group Crop Science Maintain operational targets; adapt as Continue with integration necessary from COVID-19 Focus on pipeline execution Continued focus on cash flow 3 4 Pharmaceuticals Consumer Health Progress with pipeline developments, Continue to drive growth acce
Slide 15: Annex
Pictures to be updated Post Q1 Virtual Roadshow /////////// Annex May, 2020
Slide 16: Key KPIs – Bayer Group
Key KPIs – Bayer Group [€ million] Q1 2019 Q1 2020 % y-o-y Consensus1 Net Sales 12,252 12,845 4.8 / 6.0* 12,611 EBITDA before special items 3,983 4,391 10.2% 4,102 Mainly related to acquisition and integration Special items -1,044 -615 -237 costs, restructuring costs and legal costs Reported EBITDA
Slide 17: Key KPIs by division
Key KPIs by division Crop Science Pharmaceuticals Consumer Health Reconciliation Group [€ million] Q1'19 Q1'20 Q1'19 Q1'20 Q1'19 Q1'20 Q1'19 Q1'20 Q1'19 Q1'20 Sales 6,444 6,834 4,354 4,546 1,395 1,398 59 67 12,252 12,845 Sales by region: Europe / Middle East / Africa 1,764 1,894 1,675 1,799 460 490
Slide 18: Major Pharma development portfolio projects in clinical Phase I to III
Pharma: Major Pharma development portfolio projects in clinical Phase I to III (as of April 2020) Phase I (27) Phase II (12) Phase III (8) Selitrectinib (TRK Inhibitor, formerly LOXO-195) Urothelia Cancer /// Rogaratinib (pan-FGFR Inhibitor) Prostate Cancer (mHSPC) /// Darolutamide Rogaratinib (pan-